EXAMINE THIS REPORT ON TREN

There were documented intense cases of peliosis hepatis, in some cases related to liver failure and intra-abdominal hemorrhage; liver tumors, sometimes lethal; and blood lipid modifications related to increased chance of atherosclerosis led FDA to get rid of acceptance in June 2023. Added warnings include the risks related to cholestatic hepatitis,